Reuters logo
BUZZ-Novartis AG: Big potential for heart failure drug
2014年9月2日 / 下午2点53分 / 3 年前

BUZZ-Novartis AG: Big potential for heart failure drug

** Swiss drugmaker’s U.S.-listed shares up 4 pct at $92.98

** The company said on Aug. 30 that a study showed its experimental treatment, LCZ696, cut by a fifth the risk of both cardiovascular death and hospital admissions

** Sales forecasts for the drug to treat heart failures are being ramped up by analysts

** Novartis estimates multibillion-dollar sales opportunity

** Data for LCZ696 beat expectations, worked across all groups of patients, and had no serious side-effects

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below